Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Publications

IRE1 activity regulates tumour and microenvironment cell lineage states while stratifying localised and metastatic prostate cancer.

Doultsinos D. et al, (2025)

A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease.

Thomas T. et al, (2024), Nat Immunol, 25, 2152 - 2165

Late Treatment With Autologous Expanded Regulatory T-cell Therapy After Alemtuzumab Induction Is Safe and Facilitates Immunosuppression Minimization in Living Donor Renal Transplantation.

Brook MO. et al, (2024), Transplantation, 108, 2278 - 2286

Regulatory cell therapy for kidney transplantation and autoimmune kidney diseases.

Ho QY. et al, (2024), Pediatr Nephrol

Multiscale topology classifies cells in subcellular spatial transcriptomics.

Benjamin K. et al, (2024), Nature

Gene editing ofCD3 epsilongene to redirect regulatory T cells for adoptive T cell transfer

Du W. et al, (2024)

Opportunities for High-plex Spatial Transcriptomics in Solid Organ Transplantation.

Cross AR. et al, (2023), Transplantation, 107, 2464 - 2472

Spatial transcriptomic characterization of COVID-19 pneumonitis identifies immune circuits related to tissue injury.

Cross AR. et al, (2023), JCI Insight, 8

A GMP Protocol for the Manufacture of Tregs for Clinical Application.

O'Neil A. et al, (2023), 2559, 205 - 227

Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection.

VanDyke D. et al, (2022), Cell Rep, 41

Low dose interleukin-2 selectively expands circulating regulatory T cells but fails to promote liver allograft tolerance in humans.

Lim TY. et al, (2022), J Hepatol

Regulatory T cell therapy approaches.

McCallion O. et al, (2022), Clin Exp Immunol

Ex vivo-expanded human CD19+TIM-1+ regulatory B cells suppress immune responses in vivo and are dependent upon the TIM-1/STAT3 axis.

Shankar S. et al, (2022), Nat Commun, 13

Hermansky-Pudlak syndrome type 1 causes impaired anti-microbial immunity and inflammation due to dysregulated immunometabolism.

Cavounidis A. et al, (2022), Mucosal Immunol, 15, 1431 - 1446

Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection

VanDyke D. et al, (2022)

SARS-CoV-2-Specific T Cell Responses Are Not Associated with Protection against Reinfection in Hemodialysis Patients.

Shankar S. et al, (2022), J Am Soc Nephrol, 33, 883 - 887

Transplantation Without Overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients.

Brook MO. et al, (2022), BMJ Open, 12

Dampened inflammatory signalling and myeloid-derived suppressor-like cell accumulation reduces circulating monocytic HLA-DR density and associates with malignancy risk in long-term renal transplant recipients

Bottomley MJ. et al, (2022)

A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer

Fletcher CE. et al, (2022), Molecular Cancer, 21, 82 - 82

Chimeric Antigen Receptors and Regulatory T Cells: The Potential for HLA-Specific Immunosuppression in Transplantation

Wright S. et al, (2022), ENGINEERING, 10, 30 - 43

Load More